Callisto SAS

LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- OKYO Pharma Limited ("OKYO" or the "Company") today announces that Bernard Denoyer has been appointed as a non-executive director of the Company with immediate effect. Bernard F. Denoyer (age: 74) Bernard F. Denoyer has 49 years of financial management experience including his service as Senior Vice President, Finance and Secretary of development stage Synergy Pharmaceuticals, Inc. (NASDAQ: SGYP) from July 2008 until FDA approval and his retirement in June 2017. From January 2004 until January 2013. Mr. Denoyer concurrently served as Principal Financial Officer of Synergy’s former parent company, Callisto Pharmaceuticals, Inc. While with SGYP and CLSP he supported over $500M of public and PIPE financings with related due diligence, SEC registrations and market listings. From October 2000 to December 2003, Mr. Denoyer was an independent consultant, providing interim CFO and other services to emerging businesses, including Callisto and certain portfolio companies of Marsh & McLennan Capital, LLC. From October 1994 until September 2000, Mr. Denoyer served as Chief Financial Officer and Senior Vice President of META Group, Inc., an information technology research company. Mr. Denoyer earned his CPA with Ernst & Young in 1975. He received a Masters Certificate of Accounting from the Kellogg Graduate School of Management in 1974, an MBA in Finance with honors from Columbia Business School in 1972, and a BA in Economics from Fairfield University in 1969. Mr. Denoyer is fluent in French and studied in Paris at l’Istitut d’Etude Politique et Economique in 1968. He served in U.S. Army in Vietnam from 1969 to 1971 and has been an adjunct accounting professor at Fairfield University and the Marymount College. He is currently serving on the Board of Trustees for two 501(c)3 not-for-profits, St. Edmunds Retreat, Inc. and Midwestern Connecticut Council on Alcoholism, Inc. Mr Denoyer will assume the role chair the Nomination Committee of the Board from Mr Gabriele Cerrone (who will continue to serve as a member of the Nomination Committee). With immediate effect Willy Simon will assume the role of senior non-executive and will continue to chair the Remuneration Committee of the Board. Gabriele Cerrone, Chairman of OKYO, said, "We are delighted that Bernard has joined the Board of OKYO. His expertise will be of great value to us at a very important time for the group." There are no other disclosures to make pursuant to Listing Rule 9.6.13, in respect of Mr Denoyer's appointment. The person who approved the content of this announcement for purposes of UK MAR was Dr Gary Jacob, Chief Executive Officer. About OKYO OKYO Pharma Limited (LSE: OKYO) is a life sciences and biotechnology company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN. Enquiries: OKYO Pharma Limited Gabriele Cerrone +44 (0)20 7382 8300 Optiva Securities Limited Robert Emmet +44 (0)20 3981 4173 For further information, please visit the Company's website at

NEW YORK, May 15 /PRNewswire-FirstCall/ -- Callisto Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development of new drugs to treat cancer and inflammatory diseases, announced today that an article citing the history of its anti-cancer drug Atiprimod appeared in Genetic Engineering & Biotechnology News (GEN) (May 1, 2007). Genetic Engineering & Biotechnology News (GEN), the only high-frequency publication dedicated to biotech news, was introduced in 1981, as the first biotechnology trade publication. GEN is now the most widely read bionews publication worldwide. You may read the article at the following URL. The article in print also has a Figure image describing the mechanism of action of atiprimod. The article is available on the Genetic Engineering & Biotechnology News website at . About Callisto Pharmaceuticals, Inc. Callisto is a biopharmaceutical company focused on the development of new drugs to treat various forms of cancer and other serious afflictions. Callisto's drug candidates in development currently include anti-cancer agents in clinical development, in addition to drugs in pre-clinical development for other significant health care markets, including ulcerative colitis. One of the Company's lead drug candidates, Atiprimod, is in development to treat advanced carcinoid cancer, a neuroendocrine tumor, and in relapsed or refractory multiple myeloma, a blood cancer. Atiprimod is currently in a Phase II clinical trial in advanced carcinoid cancer patients, and in Phase I/IIa human clinical trials in relapsed or refractory multiple myeloma patients, respectively. A second anti-cancer drug, L-Annamycin, is being developed as a treatment for forms of relapsed or refractory acute leukemia, a currently incurable blood cancer. L-Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives. Callisto also has drugs in preclinical development for gastro-intestinal inflammation, and cancer. Guanilib is the lead candidate of our Guanylate Cyclase Receptor Agonist (GCRA) platform. Callisto own worldwide patent coverage for therapeutic applications of Guanilib in cancer and GI inflammatory diseases. Guanilib is expected to enter clinical trial in inflammatory bowel disease in 2008. Callisto has exclusive worldwide licenses from AnorMED Inc. and M.D. Anderson Cancer Center to develop, manufacture, use and sell Atiprimod and L-Annamycin, respectively. Callisto is also listed on the Frankfurt Stock Exchange under the ticker symbol CA4. More information is available at . Forward-Looking Statements Certain statements made in this press release are forward-looking. Such statements are indicated by words such as "expect," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Callisto believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the Callisto Pharmaceuticals Form S-3/A declared effective on February 15, 2007, and its periodic reports, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that products that appeared promising in early clinical trials do not demonstrate efficacy in larger-scale clinical trials, the risk that Callisto will not obtain approval to market its products, the risks associated with dependence upon key personnel and the need for additional financing. Callisto Pharmaceuticals, Inc. CONTACT: Dan D'Agostino of Callisto Pharmaceuticals, Inc.,+1-212-297-0010, ext. 227, or dagostino@callistopharma.com Web site: